We presented a retrospective study showing that from patients not  receiveing alllo-HCT at CR-1, at 10 years 16.6% of patients aged <60  years and 2.4% of those aged ≥60 years were alive and disease-free. This  disease-free AML group consisted predominantly of patients with  core-binding factor AML with t(8;21)(q22;q22) or  inv(16)(p13q22)/t(16;16)(p13;q22) and...

Human herpesvirus 6 as a possible cause of pleuropericardial effusion in patients with hematologic malignacies after allogeneic transplantation.   Presenter: Dr Lekka Participants: Prof.Spyridonidis, Dr Liga, Dr Spyridis, Dr Bountouris

The study from the French group with positive results in gene therapy for Transfusion dependent Thalassemia patients was presented. We discussed the ended of conditioning in these patients with busulphan. Furthermore we discussed the need of busulphan levels in specific patients (eg children, thalssemia...

We discussed a case of isolated CNS relapse of an ALL ph + after BMT.  Interestingly the CNS relapse revealed with an AML clone. We discussed  the current literature. We specifically reviewed the cases in Table 3 of the paper attached. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr...

Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation Presenter: Dr Spyridis  Participants: Prof.Spyridonidis, Dr Liga, Dr Lekka, Dr Bountouris

If uncommon haplotype then a MUD search may be commited. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Bountouris

A patient of ours with hhv6 viremia reveled pleuritis and pericardial infusion. Dr Lekka reviewed the literature and presented two case reports with hhv6 associated pericarditis. Presenter: Dr Lekka Participants: Prof.Spyridonidis, Dr Liga, Dr Spyridis, Dr Bountouris

Έγινε παρουσίαση της Δημοσίευσης της εγκριτικής μελέτης του EPREX στο Leukemia 2018 και συζητηθηκε ο αλγοριθμος θεραπειας στα MDS low risk. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas

Two retrospective studies from EBMT and CIBMTR verified that  conditioning intensity plays a role in BMT for AML. We discussed the  terms myeloablative, RIC, RTC, NMA, lymphodepleting. Dr. Spyridonidis  presented his new (EBMT) intensity index. Presenter: Prof. Spyridondis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas

The antiviral prophylaxis for cytomegalovirus infection in allogeneic  hematopoietic cell transplantation was reviewed. Prophylaxis reduse CMV  reactivation and disease but has little effect on OS in older studies,  except the newly published letermovir study. We discussed our current practice. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas

A transplantational research project showing that the combined Tx of CBU and  multiple allogeneic progenitors may facilitate early engraftment without  affecting the long term engraftment of the single CBU. Presenter:Prof.Spyridonidis Participants: Dr.Liga, Dr.Spyridis, Dr.Aggelinas

We discussed an excellent article published in NEJM regarding the clinical value of PDL1 expression. Presenter:Prof.Spyridonidis Participants: Dr.Liga, Dr.Spyridis, Dr.Aggelinas

The significance of HHV6 viremia was discussed. Presenter:Prof.Spyridonidis Participants:Dr.Liga, Dr.Spyridis, Dr.Aggelinas

A study entitled "Graft-versus-host disease in recipients of male  unrelated donor compared with parous female sibling donor transplants"  was presented. This was  a retrospective cohort study in adults with acute myeloid  leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome, who  underwent T-cell replete HCT from these 2 donor types (parous female  sibling...

A retrospective study  comparing sibling vs PTCY haplo was presented Patient age, 18 to 54 years: comparable survival after transplants from  an HLA-matched sibling and a haploidentical sibling. Patient age, 55 to 76 years: better survival after transplants from an  HLA-matched sibling compared with offspring. Presenter: Prof.Spyridonidis Participants: Dr.Liga, Dr.Spyridis,...

The use of defibrotide in blood and marrow transplantation was discussed. Presenter: Prof. Spyridonidis Participants: Dr.Liga, Dr.Spyridis, Dr.Aggelinas

A paper in BV entitled "Prediction of cardiovascular disease among  hematopoietic cell transplantation survivors" was presented. Presenter: Prof. Spyridonidis Participants: Dr.Liga, Dr Spyridis, Dr. Aggelinas

Based on a case of our unit we discussed "Outcomes of patients who  developed subsequent solid cancer after hematopoietic cell  transplantation" Presenter:Prof.Spyridonidis Participants:Dr.Liga, Dr.Spyridis, Dr.Aggelinas